2 Minute Medicine Rewind October 13, 2025
Rate of incident dementia and care needs among older adults with new traumatic brain injury: a population-based cohort study 1. ...
Tag: Gastroenterology
The proportion of gastrointestinal bleeding-related computed tomographic angiography examinations may be rising with a drop in diagnostic yield
1. Between the years 2017 and 2023, the proportion of total computed tomographic angiography (CTA) examinations related to gastrointestinal bleeding ...
Use of risankizumab is effective in adult Crohn’s disease
1. In adult patients with Crohn’s disease (CD) treated with risankizumab, only 13% of patients experienced treatment failure while 23% ...
Serum albumin-to-creatinine demonstrates an inverse and non-linear relationship with the risk of non-alcoholic fatty liver disease
1. In a group of Chinese patients with normal low-density lipoprotein cholesterol (LDL-c), serum albumin-to-creatinine (sACR) showed an inverse and ...
2 Minute Medicine Rewind September 1, 2025
β-Blocker Use and Health Status Among Patients With Heart Failure With Preserved Ejection Fraction 1. In patients with heart failure ...
Trastuzumab deruxtecan leads to longer overall survival than ramucirumab plus paclitaxel in HER2-positive gastric cancer
1. In this randomized controlled trial, among adults with HER2-positive unresectable or metastatic gastric cancer who had previously progressed on ...
Ustekinumab may be superior to Vedolizumab for the treatment of Crohn’s disease
1. In patients with Crohn’s disease (CD) of the pouch following ileal-pouch anal anastomosis (IPAA) for medically-refractory ulcerative colitis (UC), ...
mFOLFIRINOX may have a limited role in pancreatic cancer in Phase II/III trial
1. In patients with metastatic pancreatic cancer, neither modified fluorouracil, leucovorin, irinotecan and oxaliplatin (mFOLFIRINOX) or S-1, irinotecan and oxaliplatin ...
Guselkumab is safe and effective in patients with moderate-to-severe Crohn’s disease
1. The Guselkumab group demonstrated significantly greater clinical and endoscopic responses versus placebo. 2. Serious adverse events were comparable, with ...
Randomized Phase III trial of Ramucirumab finds benefit for patients with refractory advanced gastric cancer
1. The addition of ramucirumab to irinotecan in patients with ramucirumab-refractory advanced or recurrent gastric or gastroesophageal cancer (AGC) did ...
